Small molecule · Inhibitor of B-cell lymphoma 2 (Bcl-2) (BCL2) · developed by K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals
Asaretoclax is an orally bioavailable inhibitor of the anti-apoptotic protein Bcl-2. It binds Bcl-2 and inhibits its activity, restoring apoptotic processes in cells that overexpress it. It is being studied in AL amyloidosis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05199337 | Phase 1/2 | Amyloidosis | Completed | ZNTL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
AL AmyloidosisAmyloidosis
Updated Nov 1, 2026. Something wrong or missing? Report it on the ZNTL page.
See ZNTL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ZNTL catalysts and pipeline →